Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 53Other hematologic neoplasm 18Plasma cell 15Myeloid 5Other neoplasm 3Dermatologic 3Sarcoma 2Thoracic 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 5744Lung Neoplasms 3716Small Cell Lung Carcinoma 1017Breast Neoplasms 667Neoplasms 616Colorectal Neoplasms 556Melanoma 479Ovarian Neoplasms 434Neoplasm Metastasis 431Pancreatic Neoplasms 386Stomach Neoplasms 332Carcinoma, Renal Cell 311Adenocarcinoma of Lung 308Squamous Cell Carcinoma of Head and Neck 304Head and Neck Neoplasms 293Prostatic Neoplasms 284Mesothelioma, Malignant 281Esophageal Neoplasms 265Mesothelioma 244Colonic Neoplasms 225Brain Neoplasms 216Urinary Bladder Neoplasms 212Triple Negative Breast Neoplasms 209Uterine Cervical Neoplasms 207Endometrial Neoplasms 174Sarcoma 171Carcinoma, Hepatocellular 158NSCLC 134Kidney Neoplasms 127Carcinoma 127

Interventions

enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Immunoproliferative Disorders × Thoracic × Clear all
NCT04104776 2025-05-15

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Novartis

Phase 1/2 Recruiting
275 enrolled
GenitourinaryGynecologicLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Endometrial Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡